Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases

Raffaello Mancini; Manfredo Tedesco; Carlo Garufi; Angelo Filippini; Stefano Arcieri; Mauro Caterino; Giuseppe Pizzi; Enrico Cortesi; Antonella Spila; Isabella Sperduti; Maurizio Cosimelli

Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases

Raffaello Mancini, Manfredo Tedesco, Carlo Garufi, Angelo Filippini, Stefano Arcieri, Mauro Caterino, Giuseppe Pizzi, Enrico Cortesi, Antonella Spila, Isabella Sperduti, Maurizio Cosimelli

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Only 5-10% of colorectal cancer patients (pts) with liver metastases are eligible for surgical resection. Regional and systemic chemotherapy represents the best therapeutic options for unresectable metastases. Materials and Methods: In a randomized phase II trial 123 pts were enrolled with a minimum follow-up of 3 years. In Arm A 58 pts were submitted to intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m²/day, while the other 65 were included in Arm B (bolus of CDDP, 24 mg/m²/day). All the pts were also given i.v. escalating doses of fluorouracil. Response was evaluated after a minimum of 3 cycles. Results: Toxicity ≥G3 was lower in Arm B. The objective response rate was 52% in all the series, the complete responses being 17.3% (17.6% vs. 17% in Arms A and B, respectively). The overall median survival was 18 months rising to 28 months in the responders. Conclusion: CDDP HAI provided similar results as FUdR in terms of response to treatment. Moreover, long-term survivors were unexpectedly observed.

Original language	English
Pages (from-to)	1837-1841
Number of pages	5
Journal	Anticancer Research
Volume	23
Issue number	2 C
Publication status	Published - Mar 2003

Keywords

Cisplatin
Colorectal cancer
Liver metastases
Regional chemotherapy

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases'. Together they form a unique fingerprint.

Cite this

Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. / Mancini, Raffaello; Tedesco, Manfredo; Garufi, Carlo; Filippini, Angelo; Arcieri, Stefano; Caterino, Mauro; Pizzi, Giuseppe; Cortesi, Enrico; Spila, Antonella ; Sperduti, Isabella; Cosimelli, Maurizio.

In: Anticancer Research, Vol. 23, No. 2 C, 03.2003, p. 1837-1841.

Research output: Contribution to journal › Article › peer-review

Mancini, Raffaello ; Tedesco, Manfredo ; Garufi, Carlo ; Filippini, Angelo ; Arcieri, Stefano ; Caterino, Mauro ; Pizzi, Giuseppe ; Cortesi, Enrico ; Spila, Antonella ; Sperduti, Isabella ; Cosimelli, Maurizio. / Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. In: Anticancer Research. 2003 ; Vol. 23, No. 2 C. pp. 1837-1841.

@article{94a8c23f68294b528df01a23c3312598,

title = "Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases",

abstract = "Background: Only 5-10% of colorectal cancer patients (pts) with liver metastases are eligible for surgical resection. Regional and systemic chemotherapy represents the best therapeutic options for unresectable metastases. Materials and Methods: In a randomized phase II trial 123 pts were enrolled with a minimum follow-up of 3 years. In Arm A 58 pts were submitted to intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day, while the other 65 were included in Arm B (bolus of CDDP, 24 mg/m2/day). All the pts were also given i.v. escalating doses of fluorouracil. Response was evaluated after a minimum of 3 cycles. Results: Toxicity ≥G3 was lower in Arm B. The objective response rate was 52% in all the series, the complete responses being 17.3% (17.6% vs. 17% in Arms A and B, respectively). The overall median survival was 18 months rising to 28 months in the responders. Conclusion: CDDP HAI provided similar results as FUdR in terms of response to treatment. Moreover, long-term survivors were unexpectedly observed.",

keywords = "Cisplatin, Colorectal cancer, Liver metastases, Regional chemotherapy",

author = "Raffaello Mancini and Manfredo Tedesco and Carlo Garufi and Angelo Filippini and Stefano Arcieri and Mauro Caterino and Giuseppe Pizzi and Enrico Cortesi and Antonella Spila and Isabella Sperduti and Maurizio Cosimelli",

year = "2003",

month = mar,

language = "English",

volume = "23",

pages = "1837--1841",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2 C",

}

TY - JOUR

T1 - Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases

AU - Mancini, Raffaello

AU - Tedesco, Manfredo

AU - Garufi, Carlo

AU - Filippini, Angelo

AU - Arcieri, Stefano

AU - Caterino, Mauro

AU - Pizzi, Giuseppe

AU - Cortesi, Enrico

AU - Spila, Antonella

AU - Sperduti, Isabella

AU - Cosimelli, Maurizio

PY - 2003/3

Y1 - 2003/3

N2 - Background: Only 5-10% of colorectal cancer patients (pts) with liver metastases are eligible for surgical resection. Regional and systemic chemotherapy represents the best therapeutic options for unresectable metastases. Materials and Methods: In a randomized phase II trial 123 pts were enrolled with a minimum follow-up of 3 years. In Arm A 58 pts were submitted to intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day, while the other 65 were included in Arm B (bolus of CDDP, 24 mg/m2/day). All the pts were also given i.v. escalating doses of fluorouracil. Response was evaluated after a minimum of 3 cycles. Results: Toxicity ≥G3 was lower in Arm B. The objective response rate was 52% in all the series, the complete responses being 17.3% (17.6% vs. 17% in Arms A and B, respectively). The overall median survival was 18 months rising to 28 months in the responders. Conclusion: CDDP HAI provided similar results as FUdR in terms of response to treatment. Moreover, long-term survivors were unexpectedly observed.

AB - Background: Only 5-10% of colorectal cancer patients (pts) with liver metastases are eligible for surgical resection. Regional and systemic chemotherapy represents the best therapeutic options for unresectable metastases. Materials and Methods: In a randomized phase II trial 123 pts were enrolled with a minimum follow-up of 3 years. In Arm A 58 pts were submitted to intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day, while the other 65 were included in Arm B (bolus of CDDP, 24 mg/m2/day). All the pts were also given i.v. escalating doses of fluorouracil. Response was evaluated after a minimum of 3 cycles. Results: Toxicity ≥G3 was lower in Arm B. The objective response rate was 52% in all the series, the complete responses being 17.3% (17.6% vs. 17% in Arms A and B, respectively). The overall median survival was 18 months rising to 28 months in the responders. Conclusion: CDDP HAI provided similar results as FUdR in terms of response to treatment. Moreover, long-term survivors were unexpectedly observed.

KW - Cisplatin

KW - Colorectal cancer

KW - Liver metastases

KW - Regional chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=12444303851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444303851&partnerID=8YFLogxK

M3 - Article

C2 - 12820466

AN - SCOPUS:12444303851

VL - 23

SP - 1837

EP - 1841

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 C

ER -